# Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

> **NCT04513717** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **NRG Oncology** · enrollment: 2753 (actual)

## Conditions studied

- Prostate Adenocarcinoma
- Stage III Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** Bicalutamide
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **DRUG:** Buserelin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Degarelix
- **DRUG:** Flutamide
- **DRUG:** Goserelin
- **DRUG:** Histrelin
- **DRUG:** Leuprolide
- **PROCEDURE:** Magnetic Resonance Elastography
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radiation Therapy
- **DRUG:** Relugolix
- **DRUG:** Triptorelin

## Key facts

- **NCT ID:** NCT04513717
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-21
- **Primary completion:** 2033-12-31
- **Final completion:** 2033-12-31
- **Target enrollment:** 2753 (ACTUAL)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04513717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04513717, "Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04513717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*